Pericyte-targeting prodrug overcomes tumor resistance to vascular disrupting agents.
Chen M, Lei X, Shi C, Huang M, Li X, Wu B, Li Z, Han W, Du B, Hu J, Nie Q, Mai W, Ma N, Xu N, Zhang X, Fan C, Hong A, Xia M, Luo L, Ma A, Li H, Yu Q, Chen H, Zhang D, Ye W.
Chen M, et al. Among authors: luo l.
J Clin Invest. 2017 Oct 2;127(10):3689-3701. doi: 10.1172/JCI94258. Epub 2017 Aug 28.
J Clin Invest. 2017.
PMID: 28846068
Free PMC article.